DarioHealth Corp. (NASDAQ:DRIO) Given Average Rating of “Hold” by Analysts

DarioHealth Corp. (NASDAQ:DRIO) has earned an average rating of “Hold” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $32.00.

A number of brokerages have commented on DRIO. Stifel Nicolaus set a $16.00 target price on DarioHealth in a research note on Friday, November 14th. Cowen reissued a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of DarioHealth in a research report on Monday. Finally, Wall Street Zen downgraded DarioHealth from a “hold” rating to a “sell” rating in a research note on Saturday.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd boosted its position in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,511 shares of the company’s stock after purchasing an additional 43,513 shares during the period. XTX Topco Ltd owned approximately 0.14% of DarioHealth worth $42,000 as of its most recent SEC filing. 33.39% of the stock is owned by institutional investors.

DarioHealth Price Performance

Shares of NASDAQ:DRIO opened at $10.52 on Friday. The company has a market cap of $71.12 million, a PE ratio of -0.94 and a beta of 1.05. DarioHealth has a fifty-two week low of $5.93 and a fifty-two week high of $31.00. The firm has a 50-day simple moving average of $12.26 and a 200 day simple moving average of $12.19. The company has a quick ratio of 4.02, a current ratio of 4.55 and a debt-to-equity ratio of 0.41.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.